p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes

Online journal article in Hematopathology that offers 1.0 continuing education (CME) credit that can be used to fulfill CC Part II requirements.

Quantity:

Want to save more?

Log into see if you qualify for a lower rate.

Members

save $5.00 or more

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

Compare the utility and application of various testing modalities for assessing residual disease in TP53-mutated acute myeloid leukemia (AML) and...

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

Compare the utility and application of various testing modalities for assessing residual disease in TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
List clinical features of TP53-mutated AML and MDS, and discuss limitations of applying measurable residual disease flow cytometry (MRD-FC) and molecular testing in evaluating residual disease.
Describe the methods used by the authors for applying p53 immunohistochemistry for rapid assessment of residual disease in TP53-mutated AML and MDS.

View More View Less